Jundishapur Journal of Microbiology

Published by: Kowsar

Expression of NS3/NS4A Proteins of Hepatitis C Virus in Huh7 Cells Following Engineering Its Eukaryotic Expression Vector

Mohammad Amin Behzadi 1 , 2 , Abdolvahab Alborzi 1 , Gholamreza Pouladfar 1 , Mehdi Dianatpour 3 , 4 and Mazyar Ziyaeyan 1 , *
Authors Information
1 Professor Alborzi Clinical Microbiology Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Stem Cell and Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: November 2015, 8 (11); e59919
  • Published Online: November 26, 2015
  • Article Type: Research Article
  • Received: January 26, 2015
  • Revised: May 21, 2015
  • Accepted: June 8, 2015
  • DOI: 10.5812/jjm.27355

To Cite: Behzadi M A, Alborzi A, Pouladfar G, Dianatpour M, Ziyaeyan M. Expression of NS3/NS4A Proteins of Hepatitis C Virus in Huh7 Cells Following Engineering Its Eukaryotic Expression Vector, Jundishapur J Microbiol. 2015 ; 8(11):e59919. doi: 10.5812/jjm.27355.

Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, et al. Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepat. 2015; 22(2): 175-83[DOI][PubMed]
  • 2. Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int. 2015; 35: 71-7[DOI][PubMed]
  • 3. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003; 290(2): 228-37[PubMed]
  • 4. Sarvari J, Norozian H, Fattahi MR, Pirbonyeh N, Moattari A. The Role of Interferon Gamma Gene Polymorphism (+874A/T, +2109A/G, and -183G/T) in Response to Treatment Among Hepatitis C Infected Patients in Fars Province, Southern Iran. Hepat Mon. 2014; 14(1)[DOI][PubMed]
  • 5. Behzadi MA, Ziyaeyan M. Hepatitis C Virus Load in Seropositive Liver and Kidney Transplant Recipients by Quantitative Real-Time PCR Before and After Transplantation. Jundishapur J Microbiol. 2013; 6(8)[DOI]
  • 6. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368(20): 1867-77[DOI][PubMed]
  • 7. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370(21): 1993-2001[DOI]
  • 8. Innes H, Goldberg D, Dillon J, Hutchinson SJ. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? Gut. 2015; : 1800-9[DOI]
  • 9. Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat. 2014; 21(3): 208-15[DOI][PubMed]
  • 10. Hill A, Cooke G. Medicine. Hepatitis C can be cured globally, but at what cost? Science. 2014; 345(6193): 141-2[DOI][PubMed]
  • 11. Lohmann V, Koch JO, Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J hepatol. 1995; 24(2 Suppl): 11-9[PubMed]
  • 12. Omran MH, Nabil W, Youssef SS, El-Sayed M, El Awady MK. Heterogeneity and New Epitopes of Hepatitis C Virus Genotype 4. Hepat Mon. 2013; 13(8)[DOI][PubMed]
  • 13. Anjum S, Ali S, Ahmad T, Afzal MS, Waheed Y, Shafi T, et al. Sequence and Structural Analysis of 3' Untranslated Region of Hepatitis C Virus, Genotype 3a, From Pakistani Isolates. Hepat Mon. 2013; 13(5)[DOI]
  • 14. Moghadam FS, Mohebbi SR, Hosseini SM, Damavand B, Zali MR. A new subtype of hepatitis C virus genotype 3: Analysis of available evidence. Hepat Mon. 2013; 13(8)[DOI]
  • 15. Echeverria N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. World J Hepatol. 2015; 7(6): 831-45[DOI][PubMed]
  • 16. Smith HA. Regulation and review of DNA vaccine products. Dev Biol. 1999; 104: 57-62[PubMed]
  • 17. Sabet LP, Taheri T, Memarnejadian A, Azad TM, Asgari F, Rahimnia R, et al. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat Mon. 2014; 14(10)[PubMed]
  • 18. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997; 35(1): 201-7[PubMed]
  • 19. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine. 2008; 26(49): 6225-31[DOI][PubMed]
  • 20. Weiland O, Ahlen G, Diepolder H, Jung MC, Levander S, Fons M, et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther. 2013; 21(9): 1796-805[DOI][PubMed]
  • 21. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996; 98(3): 706-14[PubMed]
  • 22. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Pape GR, Wierenga EA, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995; 346(8981): 1006-7[PubMed]
  • 23. Khanlari Z, Sabahi F, Hosseini SY, Ghaderi M. HCV NS3 Blocking Effect on IFN Induced ISGs Like Viperin and IL28 With and Without NS4A. Hepat Mon. 2014; 14(4)[DOI][PubMed]
  • 24. Hosseini SY, Sabahi F, Moazzeni SM, Modarressi MH, Saberi Firoozi M, Ravanshad M. Construction and Preparation of Three Recombinant Adenoviruses Expressing Truncated NS3 and Core Genes of Hepatitis C Virus for Vaccine Purposes. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 25. Ullah S, Shah MA, Riaz N. Recent Advances in Development of DNA Vaccines Against Hepatitis C virus. Indian J Virol. 2012; 23(3): 253-60[DOI][PubMed]
  • 26. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011; 54(6): 1273-85[DOI][PubMed]
  • 27. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61(1): 77-87[DOI][PubMed]
  • 28. Sefidi FJ, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon. 2013; 13(1)[DOI]
  • 29. Feyznezhad R, Behzadi MA, Yaghobi R, Ziyaeyan M. Determining major genotypes of hepatitis C virus among transplant recipients by real-time polymerase chain reaction assay. Jundishapur J Microbiol. 2015; 8(2)[DOI][PubMed]
  • 30. Wolk B, Sansonno D, Krausslich HG, Dammacco F, Rice CM, Blum HE, et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol. 2000; 74(5): 2293-304[PubMed]
  • 31. Tanji Y, Hijikata M, Satoh S, Kaneko T, Shimotohno K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J Virol. 1995; 69(3): 1575-81[PubMed]
  • 32. Frelin L, Alheim M, Chen A, Söderholm J, Rozell B, Barnfield C, et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther. 2003; 10(8): 686-99[PubMed]
  • 33. Williams JA. Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. Vaccines (Basel). 2013; 1(3): 225-49[DOI][PubMed]
  • 34. Hasan UA, Abai AM, Harper DR, Wren BW, Morrow WJW. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immun Methods. 1999; 229(1): 1-22[DOI]
  • 35. Yang J, Zhang Z, Lin J, Lu J, Liu B, Zeng S, et al. Detection of MMP activity in living cells by a genetically encoded surface-displayed FRET sensor. Biochimica et Biophysica Acta . 2007; 1773(3): 400-7[DOI]
  • 36. Puttikhunt C, Kasinrerk W, Srisa-ad S, Duangchinda T, Silakate W, Moonsom S, et al. Production of anti-dengue NS1 monoclonal antibodies by DNA immunization. J Viroll Methods. 2003; 109(1): 55-61[PubMed]
  • 37. Haddad D, Liljeqvist S, Kumar S, Hansson M, Ståhl S, Perlmann H, et al. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med Microbiol. 1995; 12(3‐4): 175-86[PubMed]
  • 38. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine. 1999; 17(15): 1992-2002[PubMed]
  • 39. Alvarez-Lajonchere L, Duenas-Carrera S. Advances in DNA immunization against hepatitis C virus infection. Hum Vaccin. 2009; 5(8): 568-71[PubMed]
  • 40. Ullah S, Shah MAA, Riaz N. Recent advances in development of DNA vaccines against hepatitis C virus. Indian J Virol. 2012; 23(3): 253-60[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments